Experience

Cardiac-Tech Ltd

• United Kingdom
• Medical Device
• 1 - 100 Employee

• Chairman

  • Apr 2023 - Present

  Following open heart surgery, patients often experience rhythm disturbances which can lead to serious complications during recovery. To counter this, cardiac surgical patients are typically fitted with a temporary pacing system in order to regulate the heart’s rhythm and ensure a near-normal cardiac output is maintained. Post-surgical temporary pacing therapy is achieved by attaching a pacing wire to the outer surface of the heart, feeding the wire through the patient’s abdomen, and attaching this to an extension lead which is inserted into a temporary pacing device that is kept at the bedside. Research and experience show epicardial pacing wires to be both unstable and subject to degeneration from epithelialisation (scar tissue formation), with published articles highlighting the potential dangers of temporary pacing and recommending that checks on the pacing parameters of such devices be performed at least every 12 hours. This instability, coupled with devices that lack the sophistication seen in modern permanent pacing, as well as device management typically undertaken by ITU doctors and nurses operating in high pressured environments, can lead to a failure to identify acute and sudden changes in device function or patient underlying rhythm. As a result, cardiac output may be affected, resulting in higher use of inotrope (muscle contraction) medication and an extended and costly ITU stay. Other more serious consequences of a failure to recognize acute changes in pacing function can lead to serious harm to the patient, including causing cardiac arrest and death. Show less



LuSeed Vascular

• Medical Equipment Manufacturing
• 1 - 100 Employee

• Vice Chairman of The Board

  • Dec 2022 - Present

  This first-in-category Intrasaccular Device to be used as acute and long-term solution, For both bifurcation and sidewall aneurysms This first-in-category Intrasaccular Device to be used as acute and long-term solution, For both bifurcation and sidewall aneurysms



MIVI Neuroscience, Inc

• United States
• Medical Device
• 1 - 100 Employee

• Vice Chairman Of The Board

  • Mar 2020 - Present

  MIVI is on a mission to deliver groundbreaking solutions for improving outcomes in challenging neurointerventional procedures. We go beyond current options to solve two major unmet needs identified by neurointerventionalists—improving aspiration outcomes for strokes, and reducing distal embolization. MIVI is on a mission to deliver groundbreaking solutions for improving outcomes in challenging neurointerventional procedures. We go beyond current options to solve two major unmet needs identified by neurointerventionalists—improving aspiration outcomes for strokes, and reducing distal embolization.



Tahoe Prosperity Center

• United States
• Civic and Social Organizations
• 1 - 100 Employee

• Board Member

  • Nov 2011 - Present

• Chairman and Vice Chair Of The Board

  • Jan 2019 - Dec 2020

• Vice Chairman

  • Jan 2019 - Jan 2020



Sanibel Capital

• Lake Tahoe NV

• MedTech Industry Advisor Serving on Boards to Help Make a Difference

  • Nov 2017 - Present



Neuravi aquired by JNJ 2017

• Galway Ireland

• Member Board of Directors

  • Mar 2015 - Jan 2020

  Fully focused on improving acute stroke treatment, Neuravi develops and globally markets innovative medical devices for neurointerventional therapy that are based upon extensive research into the clot and occlusions that cause stroke. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke. Fully focused on improving acute stroke treatment, Neuravi develops and globally markets innovative medical devices for neurointerventional therapy that are based upon extensive research into the clot and occlusions that cause stroke. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.



Vascular Dynamics

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• President & Chief Executive Officeer

  • Oct 2011 - Nov 2017

• Board Member

  • Nov 2011 - Oct 2017

  President and Chief Executive OfficerMember of the Board Of Directors



Reverse Medical aquired by Covidien/Medtronic

• Past Board Member

  • Jan 2011 - Jan 2014

  Company sold to Covidien/MDT Company sold to Covidien/MDT



Flexible Stenting Solutions, Inc.

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Past Board Member

  • Jan 2011 - Mar 2013

  Flexible Stenting was acquired by JNJ March 2013 Flexible Stenting was acquired by JNJ March 2013



Travel Wrangler

• Board Member

  • Jan 2011 - Feb 2012



Nexeon MedSystems, Inc

• Past Board Member

  • Jan 2010 - Oct 2011



Micrus Endovascular sold to JNJ 2010

• President & Chief Operating Officer

  • Jan 2004 - Oct 2010

  Micrus Endovascular Corporation (NASDAQ: MEND) develops and markets products that are used in the minimally invasive treatment of cerebral aneurysms and ischemic stroke. Proprietary Micrus microcoils and access platforms provide a safe and reliable alternative to a highly invasive and costly neurosurgical procedure (craniotomy and aneurysmal clipping) that requires extended operating room and recovery times. Micrus’ microcoils, combined with its access products such as guidewires, balloon catheters, guide cathers and microcatheters, allow physicians to treat cerebral aneurysms less invasively through the arterial system. Micrus markets its products through a direct sales force in North America and parts of Europe, and through distributors in Japan, Europe, Latin America, Asia and the Middle East. Show less



Context Connect Inc.

• President CEO

  • Jul 2000 - Jan 2004

  Context Connect, LLC. (“CCL”) is a privately-held company dedicated to revolutionizing the way individuals ‘find and connect’ to one another, privately. Context Connect provides a proprietary technology that 1) allows for simple directory-based connectivity and other transactions between individuals, 2) retains the privacy of individual’s information and 3) generates communication-based transactions for service providers such as social networking sites and carriers. Context Connect is headquartered in Boston, Massachusetts with offices in Wellington, New Zealand. Investors in Context Connect include Equity Resource Investments, Bingham McCutchen (via the Gould Fund), Sitel Corporation and Bay Resource Corporation. The company has developed a robust portfolio of intellectual property throughout the world focused on the area of private, directory-based connectivity. The company offers a simple directory platform that allows individuals to ‘find and connect’ one another without revealing the actual contact information of the target subscriber. Through the company’s Directory as a Service (Daas) Platform, the ‘click to talk’ widgets allow people to get connected based on contextual names or aliases that they control and manage, rather than phone numbers or contact information that are 1) private to individuals and 2) hard to remember Show less



Qixel Capital Group, Inc.

• Executive Vice President

  • Jan 2000 - Jul 2000

  Qixel Capital Group, Inc. is an Internet holding company that cultivates companies focused on the development of business-to-business eCommerce in Asia/Pacific. Qixel's specialized services enhance Internet infrastructure in Southern Hemisphere and Pacific-rim countries by partnering with local companies to build efficiencies, speed learning curves and deploy proven Internet solutions in new markets. Through its existing network of eCommerce-focused companies, Qixel provides a variety of resources to enable end-to-end eCommerce solutions for nascent market entrants. Show less



InnerDyne, Inc. NASDAQ (IDYN)

• Vice President, Chief Financial Officer

  • Jan 1996 - Jan 2000

  Led, legal, accounting, and finance team through public offering as InnerDyne, Inc. Developed infrastructure, which led to profitability in 28 months after $52 million in sequential losses Developed IT and WAN systems for manufacturing and financial management Responsible for strategic planning and negotiation of corporate alliances (AHP,SDG. ) Responsible for all finance related issues including, banking, corporate finance, P&L, treasury, risk management, forecasting Responsible for IR program and buy and sell side analytical coverage. Responsible as the senior financial officer for all public filings, press releases and investor reporting Developed and filed a series of radioisotope and drug delivery patents, focused on restenosis, and oncology these technologies are currently in animal trials Show less



Rhomed Inc.

• Vice President Corporate Finance, Chief Financial Officer

  • Jan 1991 - Jan 1996

  Responsible for Worldwide technology and product licensing. Established a European business and research division. Manage all domestic and international business affairs. Negotiated all marketing, manufacturing and distribution agreements. Successfully negotiated agreements with 5 multi-national companies to commercialize three radiopharmaceutical products. Responsible for Worldwide technology and product licensing. Established a European business and research division. Manage all domestic and international business affairs. Negotiated all marketing, manufacturing and distribution agreements. Successfully negotiated agreements with 5 multi-national companies to commercialize three radiopharmaceutical products.